Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022

October 12, 2022

https://www.globenewswire.com/news-release/2022/10/12/2532699/32419/en/Matinas-BioPharma-to-Present-New-MAT2203-Oral-Amphotericin-B-Data-During-IDWeek-2022.html

Interim data from all-oral Cohort 4 of the EnACT Trial of MAT2203 in Cryptococcal Meningitis to be revealed along with an overview of the entire Phase 2 trial

Read more at globenewswire.com

Related news for (MTNB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.